Provided by Tiger Fintech (Singapore) Pte. Ltd.

Humacyte, Inc.

2.96
-0.1900-6.03%
Post-market: 2.970.0101+0.34%19:39 EST
Volume:2.66M
Turnover:8.14M
Market Cap:380.86M
PE:-2.18
High:3.29
Open:3.00
Low:2.94
Close:3.15
Loading ...

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

GlobeNewswire
·
28 Oct 2024

Humacyte to host KOL event on he use of ATEV for AV access in hemodialysis

TIPRANKS
·
23 Oct 2024

Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024

GlobeNewswire
·
23 Oct 2024

Humacyte Price Target Maintained With a $10.00/Share by BTIG

Dow Jones
·
18 Oct 2024

Stock Track | Humacyte Shares Soar on Positive Analyst Ratings and Outlook

Stock Track
·
18 Oct 2024

Humacyte issues raised in 483 appear ‘fixable,’ says BTIG

TIPRANKS
·
18 Oct 2024

Humacyte facility inspection likely not root cause of BLA delay, says TD Cowen

TIPRANKS
·
18 Oct 2024

Humacyte concerns raised in 483 not that big a deal, says Piper Sandler

TIPRANKS
·
18 Oct 2024

Stock Track | Humacyte Stock Surges Over 10% Pre-Market on Analyst Ratings

Stock Track
·
18 Oct 2024

TD Cowen Sticks to Their Buy Rating for Humacyte (HUMA)

TIPRANKS
·
18 Oct 2024

Piper Sandler Sticks to Its Hold Rating for Humacyte (HUMA)

TIPRANKS
·
18 Oct 2024

FDA discloses summary of violations at Humacyte’s Durham, NC facility

TIPRANKS
·
18 Oct 2024

Lab-Grown Blood Vessels Could Soon Become Reality -- WSJ

Dow Jones
·
16 Oct 2024

Humacyte Price Target Maintained With a $15.00/Share by Benchmark

Dow Jones
·
10 Oct 2024

Benchmark Co. Remains a Buy on Humacyte (HUMA)

TIPRANKS
·
10 Oct 2024

Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 Av Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

THOMSON REUTERS
·
08 Oct 2024